

# Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample

## SHORT TITLE

Ethical loss in randomized clinical trials

Jean-Pierre Boissel<sup>1\*</sup>, David Pérol<sup>2</sup>, Hervé Décousus<sup>3</sup>, Ingrid Klingmann<sup>4</sup>, Marc Hommel<sup>5</sup>

## AFFILIATIONS

<sup>1</sup>Novadiscovery, Lyon, France, CSO, Emeritus Professor of Clinical Pharmacology

<sup>2</sup>Department of Biostatistics, Centre Léon Bérard, Lyon, France, Head

<sup>3</sup>INSERM, CIC 1408 - F Crin, INNOVTE; CHU Saint-Etienne, Hôpital Nord, Service Médecine Vasculaire et Thérapeutique, F-42055 Saint Etienne, France, Head.

<sup>4</sup>European Forum for Good Clinical Practice (EFGCP), Brussels, Belgium, Chairwoman of the Board

<sup>5</sup>University Hospital Grenoble, EA 4407 AGEIS UGA, France, Emeritus Professor of Neurology

**\*Corresponding Author**

E-mail: jean-pierre.boissel@novadiscovery.com

20 These authors contributed equally to this work. All authors have reviewed the  
21 manuscript

## 22 ABSTRACT

23 In order to propose a more precise definition and explore how to reduce ethical losses  
24 in randomized controlled clinical trials (RCTs), we set out to identify trial participants  
25 who do not contribute to demonstrating that the treatment in the experimental arm is  
26 superior to that in the control arm. RCTs emerged mid-last century as the gold  
27 standard for assessing efficacy, becoming the cornerstone of the value of new  
28 therapies, yet their ethical grounds are a matter of debate. We introduce the concept of  
29 unnecessary participants in RCTs, the sum of non-informative participants and non-  
30 responders. The non-informative participants are considered not informative with  
31 respect to the efficacy measured in the trial in contrast to responders who carry all the  
32 information required to conclude on the treatment's efficacy. The non-responders  
33 present the event whether or not they are treated with the experimental treatment. The  
34 unnecessary participants carry the burden of having to participate in a clinical trial  
35 without benefiting from it, which might include experiencing side effects. Thus, these  
36 unnecessary participants carry the ethical loss that is inherent to the RCT  
37 methodology. On the contrary, responders to the experimental treatment bear its entire  
38 efficacy in the RCT. Starting from the proportions observed in a real placebo-  
39 controlled trial from the literature, we carried out simulations of RCTs progressively  
40 increasing the proportion of responders up to 100%. We show that the number of  
41 unnecessary participants decreases steadily until the RCT's ethical loss reaches a  
42 minimum. In parallel, the trial sample size decreases (presumably its cost as well),  
43 although the trial's statistical power increases as shown by the increase of the chi-  
44 square comparing the event rates between the two arms. Thus, we expect that  
45 increasing the proportion of responders in RCTs would contribute to making them  
46 more ethically acceptable, with less false negative outcomes.

47

## 48 INTRODUCTION

49 Ethical loss in randomized controlled clinical trials (RCTs) is an intuitive and rather  
50 vague concept, which can be outlined at a first glance as a loss of chance, i.e.  
51 everything an individual either misses or experience as detrimental as a result of  
52 participating in a RCT. The uncertainty associated with trial enrollment has two  
53 opposite issues. In an attempt to address these two opposite uncertainties, Freedman  
54 proposed the concept of “equipoise”. [1] RCTs remain the gold standard for  
55 evaluating the efficacy and safety of new therapies. [2,3] Despite their wide  
56 acceptance and applying the principle of ‘equipoise’, some questions of ethics in  
57 RCTs remain unanswered. There are various types of ethical concerns linked to  
58 randomization: prior to launching a trial of a new treatment, randomizing participants  
59 to conventional treatments that is deemed less effective is a breach of the equipoise  
60 principle, just as happen with allocation to a placebo, or to a known sham treatment;  
61 once the trial is completed, if the experimental treatment turns out to be either more  
62 effective or less effective (or even potentially harmful), participants in the control arm  
63 or those in the experimental arm, respectively, face a loss of chance. If the required  
64 informed consent is usually presented as a measure to overcome [4] these issues, in  
65 reality it potentially transfers part of these concerns from investigators to participants.  
66 Several alternatives to traditional RCTs have been proposed recently to address some  
67 of these ethical concerns: adaptive designs enabling planned interim analyses that can  
68 lead to a reduction of the total number of randomized participants or to a deletion of  
69 study arms with inefficient treatment regimens and re-randomization of subjects to the  
70 more promising treatment arms; and external control arms that suppressed the need to  
71 randomize participants to the ‘conventional treatment’. [5,6]

72 It is known that when a new treatment is being trialed, some participants in the  
73 treatment arm will present the event the treatment is supposed to prevent, as opposed  
74 to the “responders”, i.e., those showing the expected reaction to treatment.  
75 Identification of responders is a timely and challenging issue that remains poorly  
76 studied, mainly because it is difficult to predict how participants will respond to the  
77 experimental treatment. But beyond the importance of identifying responders in the  
78 era of personalized medicine, the consequences of enrolling non-responders in RCTs  
79 remain unexplored.

80 Although intuitively, selecting responders in RCTs is a worthwhile endeavor, the  
81 benefit of designing trials that meet this goal remains unexplored. Further, there is a  
82 lack of consensus in recommending it. Large trials, recruiting with little constraints  
83 have been advocated and frequently undertaken.[7,8] Regulators advise that criteria  
84 over inclusion and exclusion criteria in phase III trials should be relaxed as much as  
85 possible,[9] while suggesting maintaining sufficient homogeneity, seeking for a  
86 compromise that is not easy to achieve.

87 The work presented here focus on the ethical issue arising from including non-  
88 responders in RCTs. More precisely, the objective of our work is to show how RCT  
89 simulations can be used to address the consequences of diluting the number of  
90 responders in the trial sample. Our simulations do not aim at quantitatively defining  
91 adequate parameters of an RCT but intend to draw upon the qualitative perception of  
92 the issue of ethical loss linked to the current way of how RCTs are planned, especially  
93 when it comes to eligibility criteria. To that extent, our approach focuses on treatment  
94 efficacy. We postulate that identifying responders could reduce uncertainty and could  
95 be viewed as an operational equipoise principle.

## 96 MATERIAL AND METHODS

### 97 Overview

98 Collected data from a published trial was used for initiating the simulations conducted  
 99 for the purpose of this study. The definitions of each category of trial participants  
 100 defined below were applied to allow for computing the required number of  
 101 participants for the five categories. The changes in different trial characteristics as a  
 102 function of the proportion of responders was explored, taking the published trial as  
 103 the point zero.

### 104 Conceptual framework of this work

#### 105 *The two separate objectives of a clinical trial*

106 When one states that a trial is “aimed at demonstrating the efficacy of X in, for  
 107 example, preventing death in patients with type 2 diabetes”, the statement has two  
 108 intertwined meanings, or objectives, one being qualitative, the other quantitative.  
 109 First, it means that the trial is expected to show that X is more effective than the  
 110 control in preventing death (qualitative objective), and second, that it will provide an  
 111 estimate of the effect size (quantitative objective). The two objectives are tightly  
 112 intertwined because the achievement of the first one depends, among others, on the  
 113 observed effect size. However, for the sake of our reasoning, these must be strictly  
 114 separated, focusing on the number of responders (a quantitative objective). Although  
 115 out of the scope of the work developed here, there are other, more fundamental,  
 116 reasons for separating these two objectives. Just to name two examples: while the  
 117 efficacy is a treatment property, which supports consideration of extrapolating the

118 context of use, the validity of the effect size estimate based on the difference between  
119 the observed rates of the event in the two arms is limited to the trial itself.

120 “Responders”, “non-responders”, “non-informative”, and “unnecessary”  
121 participants

## 122 *Definition of a responder*

123 Let us assume that the expected effect of the treatment of interest is to prevent a  
124 dichotomous (yes/no) event, such as death. In this instance, a responder is a patient  
125 who would have presented the event the experimental therapy is supposed to prevent  
126 if he/she had not been treated with this therapy, and who will not present it if treated  
127 with the therapy. In parallel-arm design, RCT with mortality endpoints, responders  
128 are subjects with a fatal outcome under control treatment (C) administration but who  
129 are kept alive if administered the experimental treatment (T). The control treatment  
130 can be the standard of care (SoC) alone, a competitor or a placebo, both on top of  
131 SoE. Although it sounds simple, in practice, this definition of responders is to today  
132 difficult, if not impossible, to apply: how to predict that a given patient is a  
133 responder? Note the assumption that the experimental treatment is better than the  
134 control, at least for a few participants, or even a single one.

## 135 *Number of responders in a two-arm RCT*

136 Let us use as an example a two-arm completed RCT with the number of event-free  
137 subjects and participants having presented the event as shown in Table 1. At baseline,  
138 the two study arms are supposed to be identical, thanks to randomization. Although in  
139 the real world, the blind randomizing process is aimed at producing two groups

140 identical on average, we will assume that all subjects included in the trial display  
141 similar baseline characteristics, i.e. are exchangeable.

142 The event rates are defined as  $R_c = a/N_c$  and  $R_T = b/N_T$  in the control and  
143 experimental treatment groups, respectively. The experimental treatment efficacy is  
144 measured by the absolute benefit,  $AB = R_c - R_T$ , but other efficacy metrics have been  
145 also described.[6] A statistical test on the observed value of the chosen metrics  
146 enables us to conclude on the materiality of the treatment efficacy. The metrics  
147 absolute value and its corresponding confidence interval are used to translate the size  
148 of the efficacy observed in the trial to a different setting.[10]

149 **Table 1.** Summary data of a completed RCT.  $a, b, c, d$  are number of patients in each  
150 cell and  $N_c$  and  $N_T$  the total number of patients in the control and the experimental  
151 arms respectively

	Control arm (C)	Experimental treatment arm (T)
Event	$a$	$b$
No event	$c$	$d$
Total	$N_c$	$N_T$

152 *How many responders in an RCT?*

153 Should the experimental treatment be effective, this translates in a true  $R_c$  greater  
154 than the true  $R_T$ . Moving forwards, observed values are assumed as the true values. In  
155 the experimental treatment arm, there are responders, who encompass the difference  
156 in magnitude of effect compared to the control arm. Since all subjects included in the  
157 trial are assumed identical, there is a responder counterpart in the control arm.

158 Designated ‘potential’ responders, unlike responders in the experimental therapy arm,  
159 they will not benefit from participating in the trial.

160 Since all participants are assumed exchangeable, they are in fact identical and we can  
161 apply the definition of responders given above. According to that same definition, the  
162 number of responders in the experimental therapy arm is given by  $d_1 = (R_c - R_T) \cdot N_T$ .  
163 In fact, they are among the ‘ $d$ ’ participants in the experimental therapy arm who will  
164 not develop the event (Table 1). The remaining of the ‘ $d$ ’ patients,  $d_2$ , are those who  
165 would not have presented the event when not receiving the experimental treatment.  
166 The total number of responders in the trial, i.e. the number of responders in the  
167 experimental treatment arm plus the number of potential responders in the control  
168 arm, is  $(R_c - R_T) \cdot (N_c + N_T)$ .

#### 169 *“Non-informative” and “unnecessary” participants*

170 We introduce the concept of unnecessary and non-informative participants in RCTs.  
171 Non-informative participants are subjects who will not present the event regardless of  
172 being treated or not with the experimental therapy. They are considered not  
173 informative with respect to the efficacy measured in the trial as opposed to  
174 responders, who carry all the information required to conclude on the treatment’s  
175 efficacy. On the other hand, unnecessary participants are all the subjects who do not  
176 benefit from participating in the trial regarding the prevention of the event, that is to  
177 say, non-responders and non-informative participants. Non-responders will present  
178 the event whether treated or not with the experimental treatment. These unnecessary  
179 participants carry the burden of having to participate in a clinical trial without  
180 benefiting from it, which might include experiencing side effects. These various  
181 categories are illustrated in Table 3, in the Results section.



## 182 *How many non-responders in this RCT?*

183 According to our definition of responders, the non-responders are those subjects who  
184 would experience the event regardless of being administered the experimental  
185 treatment or not. Their number in the experimental treatment arm is ' $b$ ' and  $a - (R_c -$   
186  $R_T).N_c$  in the control group. Their total number is  $(a + b) - (R_c - R_T).N_c$ .

## 187 *How many non-informative and unnecessary participants are included in a trial?*

188 Let us deal first with the primary objective of a RCT, which is to generate evidence to  
189 support the efficacy, i.e. reduces the rate of the event of interest, of the experimental  
190 treatment that happens when the observed difference in rates  $R_c - R_T$  is large enough  
191 to rule out the play of chance. Looking at the figures in Table 1 from a purely  
192 theoretical point of view, the gold standard statistical significance can be achieved,  
193 among other means, by decreasing ' $c$ ' and ' $d$ ', the number of recruited subjects who  
194 will not present the event, whatever the arm they have been randomly allocated to.  
195 These ' $c + d$ ' participants do not carry any information regarding the primary  
196 objective of the trial. Their main "role" in the trial is to provide a denominator value  
197 for computing the rates,  $R_c$  and  $R_T$ . As noted above, the responders in the treatment  
198 arm are hidden in ' $d$ '. These  $(R_c - R_T).N_T$  participants are in effect the only ones to  
199 benefit from participating in the trial. Further, they carry the efficacy as captured in  
200 the trial. For this reason alone, they must be counted apart. Participants  $c + d - (R_c -$   
201  $R_T).N_T$  are said "non-informative" for they do not contribute with real pharmacologic  
202 effect from the experimental treatment. Elaborating on this same reasoning, the non-  
203 responders are unnecessary participants for they do not bring into the trial a part of the  
204 experimental treatment efficacy and they cannot (when they were allocated to the  
205 control arm) or do not (experimental treatment arm) benefit from the treatment. In

fact, as shown later by the simulation, a ‘perfect’ trial does recruit only responders. In total, the number of unnecessary participants in clinical trial is  $(c + (d - R_T.N_T)) + (a + b) - N_R$ . Hence, we identified and defined four categories of participants in a trial, the last category of which being the sum of the two previous ones (see Table 3): responders, non-responders, non-informative and unnecessary participants, totaling the number of non-responders and non-informative participants.

## Ethical losses and unnecessary participants

A source of recurring dispute within RCTs is their ethical acceptability. For an individual, participating in an RCT can mean different types of ethical loss. For example, exposure to side-effects, loss of access to standard care, or loss of access to the best available and tailored treatment, or other more subtle, if not less detrimental, types of ethical loss such as moral distress or the feeling of being misled by scientists, pharmaceutical companies or even the society. There are, of course, benefits: best care administered for free, chance to be given a new, more effective treatment, to name a few. However, given the diversity of individuals, it is impossible to ensure a positive benefit-loss balance for each participant. There is, therefore, an ethical obligation to minimize the number of participants enrolled for whom the benefit-loss balance would be negative. When the outcome of interest is deemed serious or life-threatening, and death is certainly the most serious one, the marginal benefits, whatever they are, can be disregarded and ethical loss defined as any participant enrolled in the trial who is not a responder. Therefore, the number of ethical losses is  $(N_C + N_T) - (R_C - R_T).N_T$ .

## 228 *A simplified trial summary data*

229 A total of 7020 participants with type II diabetes were randomized to either the  
 230 control treatment (C), i.e. placebo, or empagliflozin (T) in the Empa-REG-Outcome  
 231 trial.[11] In this trial, twice as many participants were randomized to the experimental  
 232 treatment arm compared to a control arm. For the sake of simplicity, an assumption  
 233 was made that the experimental treatment had no other effect than preventing death,  
 234 which was not the case in the actual trial. And, instead of using the composite primary  
 235 endpoint used in the original trial, mortality from any cause was chosen, which is  
 236 straightforward in its validity and interpretation, in the Empa-REG trial and facilitates  
 237 simulations without altering the interpretation of their results. Mortality figures in this  
 238 simplified version of the original trial are given in Table 2.[11]

239 **Table 2.** Mortality figures in the Empa-REG-Outcome Trial [11]

	Placebo (C)	Treatment (T)	Total
<b>Deceased</b>	194	269	463
<b>Alive</b>	2139	4418	6557
<b>Total</b>	2333	4687	7020

## 240 *Assumptions*

241 For the sake of simplicity, a first assumption was made that the probability of death of  
 242 non-responders was constant. This assumption does not apply in real life for a given  
 243 disease, the untreated outcome probability varies from one subject to another, thus  
 244 from one trial to another. Second, the only subgroup that remained the same in our

simulations was that of the responders in the experimental treatment arm, i.e. those participants who benefited from having been enrolled in the trial.

## Simulations

Formulas developed in the previous sections were coded in an Excel spreadsheet and applied to the mortality figures in the Empa-REG-Outcome Trial [11] (Table 2). RCT simulations were carried out varying the proportion of responders. In contrast, as said above, the number of participants in the subgroup of responders in the T arm was kept constant ( $n=121$ , see below in the results section). It was assumed that, for unnecessary participants, the “true” probability of death while untreated is the observed death rate,  $R_c$ , in the control arm that remained constant across all simulated trials. At each increment of the proportion of responders (0.025), a new RCT arises, and the following values were computed from the new RCT’s summary data (Table 1): the number of ethical losses, trial sample size, observed relative risk (RR), and chi-square value for testing drug efficacy. The starting proportion is 1, a value corresponding to the “perfect” trial where all enrolled participants are responders (see below). The final proportion is 0.025, since a proportion that equals 0 results in infinite values. Note that the proportion of responders in the Empa-REG-Outcome trial is 0.023. Computations were done using an Excel spreadsheet. The numerical values of the participants were rounded to the closest unit.

## 264 RESULTS

265 *How many subjects per category are behind mortality information in the simplified*  
 266 *trial?*

267 One of the measures of efficacy in RCTs is the relative risk (RR); in our simplified  
 268 trial, derived from the Empa-REG-Outcome trial,[11] the RR was 0.73. The  
 269 information on treatment efficacy is entirely carried by the responders. The  
 270 responders do not appear as such in Table 2, and little derivation is required to bring  
 271 them off, which is explained below. Other derivations and categories of participants  
 272 enrolled in the trial are also developed below, and their results are shown in Table 3.

273 The number of expected deaths in the T group if the participant had not received the  
 274 experimental treatment is  $(194 \times (4687/2333)) = 390$ . [11] Thus, the number of  
 275 responders in the T group is  $390 - 269 = 121$ , which is another way to compute the  
 276 number of responders than the one given by definition itself,  $(R_C - R_T) \cdot N_T$ . Since the  
 277 size of the C group is about half the size of the T group, there are potential 60  
 278 responders in the C group, who, by definition, are among the 194 participants in the C  
 279 group with fatal event, i.e. death. Consequently, a total number of 181 participants  
 280  $(121 + 60)$  with a responder profile have been recruited in the Empa-REG-Outcome  
 281 trial, representing only 2.3% of the enrolled participants.

282 These 181 responders and potential responders have a counterpart, the non-  
 283 responders. This counterpart is defined as those subjects enrolled in the trial arm T for  
 284 whom the experimental treatment did not prevent death, i.e. all deceased participants  
 285 in the T arm (269), plus those participants in the C group for whom the experimental  
 286 treatment would not have prevented death, i.e. 134  $(194 - 60)$ . Note that participants

287 who stayed alive, whether treated or not, are neither responders nor non-responders,  
 288 and considered neutral regarding the drug efficacy. The total of unnecessary  
 289 participants equals  $7020 - 181 = 6839$ , while the ethical losses (i.e., all the  
 290 participants who do not benefit from enrolment in the trial regarding the primary  
 291 outcome) add up to a total  $6839 + 60$ , the potential responders in the C group. The  
 292 range of participant categories defined against response to drug T is shown in Table 3  
 293 below.

294 In this trial, all those participants who did not benefit from the experimental treatment  
 295 (i.e. 98.3% of all enrolled subjects) suffered ethical loss (i.e. 7020), minus the number  
 296 of responders in the T group, 121. Note that the degree of ethical loss depends on the  
 297 endpoints, with the maximum loss occurring if the endpoint is premature death.

298 **Table 3.** Demographic characteristics of participants.

Categories	Total N in the Empa-REG- outcome trial	Computation	Comments
Responders	181	121 (T group) + 60 (C group)	In the T arm, the number of responders is obtained by subtracting the observed number of deaths (269) from the expected number of deaths if $T = C$ , $390 = 194 \cdot (4687/2333)$ ; in the C group $60 = 121 \cdot (2333/4687)$
Non-	403	269 (T group) +	All deaths in T arm + all deaths in

responders		(194 – 60) (C group)	C arm minus the number of responders in the P arm.
Non-informative	6436	2139 (number of alive participants in the C group) + 4418 (number of alive participants in the T group) – 121 (responders in the treatment arm)	
Total of unnecessary participants	6839	6436 (non-informative) + 403 (non-responders)	This is the total number of participants minus the T responders (121) and potential responders (60)
Ethical losses	6899	6839 (total unnecessary participants) + 60 (the potential responders in the C group)	Number equals to total sample size less the number of responders (the “true” responders, those participants who benefit from enrolment in the trial)

## 299 *Relations between the proportion of responders and trial characteristics*

300 Relations between the percentage of responders and outstanding trial features (i.e.,  
 301 ethical losses, trial sample size, observed relative risk, and chi-square value for testing  
 302 drug efficacy) are shown in Figure 1 below. All other things being equal, especially  
 303 the responders and non-informative subject profiles, when the percentage of  
 304 responders in the trial sample increases from null to 100% (the “perfect” trial sample),  
 305 the ethical losses, the sample size, thus the overall trial cost, the observed relative risk  
 306 decrease, while the chi-square value increases. Since the sample size decreases, the  
 307 overall trial cost decreases, while the chi-square value increases, also increasing the  
 308 chance of demonstrating the experimental treatment’s efficacy. The overall  
 309 conclusion from these results supports the intuitive conviction that efficacy is less  
 310 likely demonstrable when responders are insufficiently represented in the trial sample.

311 **Figure 1.** Relations between the proportion of responders in the trial sample and  
 312 major features of the trial.

## 313 *The “perfect” randomized clinical trial*

314 Were it possible to recruit only responders, this amounts to the perfect RCT: i) all  
 315 treated participants who otherwise would have died will be alive by the end of the  
 316 trial; ii) the number of subjects needed to achieve the sample size for randomization  
 317 would be the lowest possible; iii) the ethical losses minimized. Here the ethical losses  
 318 amount to 60 (33.4%) of all randomized subjects (Table 4). We notice that even in  
 319 this “perfect” RCT, there is an inescapable, although minimized, ethical loss.



320 **Table 4.** Ethical losses

	C	T	
Deceased	60	0	60
Alive	0	121	121
	60	121	181

321 *“Less perfect” trials*

322 No matter how much we would like it to happen, identifying responders with 100%  
 323 accuracy is nothing but a pipe dream. Among the many reasons for this is the simple  
 324 fact that the drug has not yet been tested in humans in the anticipated context of use in  
 325 real life, preventing any researcher from inferring the responder profile. However,  
 326 while work is ongoing to overcome this hurdle and identify responders’ profile ahead  
 327 of the trial as accurately as possible, we explored the consequences of progressively  
 328 increasing the proportion of responders in our simulated example in Figure 1,  
 329 showing that ethical losses, the required trial sample size and the relative risk all  
 330 decrease, while the probability of ascertaining trial significance increases.

331 **DISCUSSION**

332 The results and their derivation share a series of disruptive points that deserve  
 333 discussion.

334 *Limitations of this study*

335 Our study has some limitations relating to the theoretical nature of the approach used  
 336 to conduct the simulations presented here. Could these limitations reduce the impact

337 of the results obtained? In a real trial, participants are not interchangeable; they may  
 338 withdraw or disappear, may take the treatment incorrectly, and may have been  
 339 wrongly classified as eligible. For simplicity, it was decided to dismiss these potential  
 340 limitations. Taking into account the non-compliance with the trial procedures and  
 341 treatment would lead to different figures in Table 3 but would not change the  
 342 direction of the results. Moreover, we have made it clear from the outset that the study  
 343 objective was of qualitative and not quantitative nature.

344 The impact of the participant interchangeability hypothesis is more difficult to assess.  
 345 Imagine that the individuals included in the trial are grouped into clusters of similar  
 346 characteristics. Within a cluster, participants are interchangeable. From one cluster to  
 347 another, the proportion of responders might vary. If we apply the same approach to  
 348 each cluster, the overall result will remain qualitatively the same.

#### 349 *Ambiguity of clinical trial objectives*

350 A trial said to be “aimed at demonstrating the efficacy of X on preventing death in  
 351 patients with type 2 diabetes”, has two intertwined meanings. First, the trial is  
 352 expected to show that X is more effective than the control, and second, that it will  
 353 provide an estimate of the effect size. We have shown that observed efficacy in the  
 354 trial and therefore the chance to demonstrate efficacy is dependent on the proportion  
 355 of responders, whereas the genuine efficacy of the experimental treatment is a  
 356 property that is independent of this proportion.

#### 357 *Is treatment efficacy carried by responders in full?*

358 Traditionally, response to treatment and the treatment effect size are the cornerstones  
 359 of efficacy demonstration for any RCT. Such assumptions have two major

360 consequences. First, efficacy is diluted across the entire sample of participants. By  
 361 applying the responder paradigm, as shown here, efficacy is no longer diluted. For the  
 362 recruited subjects, the tested treatment is or is not effective, it is a dichotomous  
 363 (yes/no) response. While such a way of looking at efficacy is acceptable for a binary  
 364 event such as death or relapse of HBV infection, for example, it seems less relevant  
 365 for a continuous outcome such as pain. However, even pain can be binarized if we  
 366 take into account each participant's own threshold of pain acceptability. Second,  
 367 translation to other populations is often achieved by applying the measured relative  
 368 risk. With this responder paradigm, efficacy indices obtained on one population are  
 369 irrelevant to another population (see panel C, Figure 1) because it is likely that the  
 370 fraction of responders will vary between populations, and so will the relative risk and  
 371 all other indices. The point here is that the proportion of subjects not at risk and  
 372 responders randomized in either arm will change, and thus the relative risk will  
 373 change accordingly. This is a consequence of the Effect Model (EM) law, a principle  
 374 that has been verified both empirically and theoretically.[12] The EM law says that  
 375 the absolute benefit in a population varies as a function of individual or sub-group  
 376 rate of events ( $R_c$ ), whatever is the treatment of interest. Therefore, both  $R_t$  and  $R_c$   
 377 vary, and so does the relative risk. The relative risk remains constant in one instance  
 378 only: when the EM is linear, which seems quite infrequent.

379 *Non-informative and/or unnecessary participant = ethical loss; how does the*  
 380 *equation fare?*

381 Central in the argumentation is the idea that data on efficacy in an RCT is only carried  
 382 by the responders. This proportion of responders is the taproot of the ethical losses

383 since, for those who are not responders, the burden of participating in a trial is not  
384 offset by the benefit expected.

385 *Is focusing on the unnecessary trial participants a way to address ethical issues in*  
386 *an RCT?*

387 As exposed in the introduction, the uncertainty raised from enrolling individuals in an  
388 RCT has two opposite uncertainties. On the one hand, the standard treatment is  
389 possibly less effective or more harmful than the experimental treatment. On the other,  
390 the standard treatment is known to be effective, whereas the efficacy of that in the  
391 experimental arm is postulated. To help handle the two opposite uncertainties,  
392 Freedman proposed the concept of “equipoise”.[1] An investigator can enroll subjects  
393 in an RCT if there is genuine uncertainty about the preferable treatment.[13] It is  
394 interesting to note that in a review of childhood oncology trials, the odds ratio for  
395 survival was 0.96, suggesting that the equipoise has been respected.[14] This finding  
396 points out to a limitation of this equipoise principle: is it ethical to launch a trial if the  
397 evidence in favor of an expected superior efficacy of the experimental treatment  
398 against the control is almost nil? Our results show that identifying responders would  
399 in fact reduce uncertainty and can be viewed as an operational equipoise principle.

400 *Is the “perfect” RCT “fully” ethical?*

401 When we considered the “perfect” RCT, with 100% of responders, we noted that the  
402 60 participants randomized to the control arm, had all deceased by the end of the trial:  
403 the ethical loss for this “perfect” RCT was 33%. Thus, even a perfect randomized trial  
404 cannot annul the number of unnecessary participants. This fact deserves three  
405 comments: i) the ethical loss can be reduced by lowering the fraction of subjects

406 randomized into the control arm; ii) however, the ethical loss in a RCT cannot be  
407 avoided; iii) increasing the proportion of responders implies that a reliable tool is  
408 required to enable their selection.

409 Other ethical issues remain for responders such as the amount and type (e.g., invasive  
410 investigations) of data collected, number of investigation time-points, confidentiality,  
411 and informed consent process.

#### 412 *Selection of responders for enrolment in RCT: neither new nor easy*

413 We demonstrated that selecting responders in RCT is of benefit to overcome ethical  
414 limitations of RCTs but also to address other practical issues, such as the trial sample  
415 size. Sequential designs were long proposed to reduce the number of subjects  
416 enrolled. [15,16] Increasing the proportion of responders is one of the arguments in  
417 favor of adaptive designs.[5] But the issue remains, how to select responders ahead of  
418 trial onset or more often during the trial. Several ways have been explored: responders  
419 identified with markers of response,[17] good compliers as assessed in a run-in  
420 phase,[18] play-the-winner,[19] discontinuation for non-responders or considerably  
421 improved participants in a run-in phase,[20] post-hoc selection, for instance, non-  
422 responders discontinuation trial designs.[21] All these attempts have not been widely  
423 adopted either because they were not proven successful, or because they are difficult  
424 to implement or because they were considered unethical.[22]

425 A tool that can identify responders before enrolment is clearly needed. More  
426 specifically, the false positive error rate must be 0. We are still far from achieving  
427 fully reliable tools, although potential solutions as to how they could be designed are  
428 now available.[23] Nevertheless, if this is achieved, the permanence of RCT as the

429 gold standard will be more strongly and more rightly challenged. Most importantly,  
 430 the design and undertaking of RCTs will have to change as a result. The availability  
 431 of tools for selecting responders will raise two challenging issues: the validation and  
 432 implementation of responder selection. The reduced sample size is an additional  
 433 consequence to bear in mind. Further, should such a tool be successfully designed,  
 434 this would undoubtedly change the applicability of the concept of personalized  
 435 medicine concept as it is currently known.

## 436 Conclusion

437 The simulation reported here confirms that increasing the proportion of responders in  
 438 a RCT is worthwhile on ethical grounds, mainly because it reduces the number of  
 439 subjects enrolled who do not provide information on treatment efficacy.

440 We claim that the low proportion of responders is parallel to and a marker of the  
 441 uncertainty relating to the experimental treatment efficacy ahead of trialing new  
 442 drugs. Scannel and Bosley have shown that, currently, drug development processes  
 443 are poorly informative.[24] According to new policies issued by the FDA and EMA,  
 444 performing *in silico* clinical trials might be a solution to improve the efficiency of  
 445 R&D by reducing uncertainty across all the stages.[25-27] Individualized computer  
 446 simulations could become therefore a valuable tool to identify responders ahead of  
 447 designing RCT.[12,28]

## 448 **ACKNOWLEDGMENTS**

449 Data resulting from simulations are available as supplementary material.

## 450 **Competing Interest Statement**

451 All authors have completed the Unified Competing Interest form (available on request  
452 from the corresponding author) and declare: no support from any organization for the  
453 submitted work [or describe if any]; no financial relationships with any organizations  
454 that might have an interest in the submitted work in the previous three years [or  
455 describe if any], no other relationships or activities that could appear to have  
456 influenced the submitted work [or describe if any].

## 457 **Author Contributions**

458 As the guarantor of the study, Jean-Pierre Boissel contributed to the  
459 conceptualization, data curation, formal analysis, and software as well as the  
460 development of the methodology and the original draft preparation. He also  
461 contributed, together with Marc Hommel, Ingrid Klingmann and David Pérol, to the  
462 management and coordination of the research activity planning and activation. Marc  
463 Hommel was responsible for the funding acquisition. All authors contributed equally  
464 to the validation, visualization, and review and editing of the manuscript submitted  
465 for publication.

## 466 **Thank-you's**

467 The authors thank Rita Moreira da Silva and Paulo Pacheco for their contribution to  
468 the editing and formatting of the manuscript.

469

## REFERENCES

1. Freedman B. Equipoise and the ethics of clinical research. *N Engl J Med*. 1987;317: 141–5 doi: 10.1056/NEJM198707163170304
2. Saad ED, Paoletti X, Burzykowski T, Buyse M. Precision medicine needs randomized clinical trials. *Nat Rev Clin Oncol*. 2017;14: 317–23. doi: 10.1038/nrclinonc.2017.8.
3. van Rosmalen BV, Alldinger I, Cieslak KP, Wennink R, Clarke M, Ali UA, et al. Worldwide trends in volume and quality of published protocols of randomized controlled trials. *PLoS One*. 2017;12: e0173042. doi: 10.1371/journal.pone.0173042.
4. Levine R, Lebacqz, K. Some ethical considerations in clinical trials. *Clin Pharmacol Ther*. 1979;25: 728–41.
5. Brown CH, Have TRT, Jo B, Dagne G, Wyman PA, Muthén B, et al. Adaptive designs for randomized trials in public health. *Annu Rev Public Health*. 2009;30: 1–25. doi: 10.1146/annurev.publhealth.031308.100223.
6. Thorlund K, Dron L, Park JJH, Mills EJ. Synthetic and External Controls in Clinical Trials – A Primer for Researchers. *Clin Epidemiol*. 2020;12: 457–467. doi: 10.2147/CLEP.S242097.
7. Remington RD. Design, and management of large multicenter clinical trials *Clin Pharmacol Ther*. 1978; 60:244-249
8. Peto R, Collins R, Gray R. Large-scale randomized evidence: large simple trials and overviews of trials *J Clin Epidemiol*.1995;48:23-40. doi: 10.1016/0895-4356(94)00150-o.



- 493 9. Statistical Principals for Clinical Trials. Available from:  
494 [https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf)  
495 [statistical-principles-clinical-trials-step-5\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf)
- 496 10. Boissel JP, Cogny F, Marko N, Boissel FH. From Clinical Trial Efficacy to  
497 Real-Life Effectiveness: Why Conventional Metrics do not Work. *Drugs Real*  
498 *World Outcomes*. 2019;6: 125–32. doi: 10.1007/s40801-019-0159-z.
- 499 11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.  
500 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.  
501 *N Engl J Med*. 2015;373: 2117–28. doi: 10.1056/NEJMoa1504720.
- 502 12. Boissel JP, Cucherat M, Nony P, Chabaud S, Gueyffier F, Wright JM, et al.  
503 New insights on the relation between untreated and treated outcomes for a  
504 given therapy effect model is not necessarily linear. *J Clin Epidemiol*.  
505 2008;61: 301–7. doi: 10.1016/j.jclinepi.2007.07.007.
- 506 13. Djulbegovic B. Acknowledgment of uncertainty: a fundamental means to  
507 ensure scientific and ethical validity in clinical research. *Curr Oncol Rep*.  
508 2001;3: 389–95. doi: 10.1007/s11912-001-0024-5.
- 509 14. Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, et al; Children's  
510 Oncology Group. Are experimental treatments for cancer in children superior  
511 to established treatments? Observational study of randomised controlled trials  
512 by the Children's Oncology Group. *BMJ*. 2005;331: 1295. doi:  
513 10.1136/bmj.38628.561123.7C.
- 514 15. Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical  
515 modelling of patient subpopulations: Efficient designs of Phase II oncology  
516 clinical trials. *Clin Trials*. 2013;10: 720–34. doi: 10.1177/1740774513497539.

- 517 16. Whitehead J. A unified theory for sequential clinical trials. *Stat Med.* 1999;18:  
518 2271–86. doi: 10.1002/(sici)1097-0258(19990915/30)18:17/18<2271::aid-  
519 sim254>3.0.co;2-z.
- 520 17. Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, et al.  
521 Comprehensive screening of target molecules by next-generation sequencing  
522 in patients with malignant solid tumors: guiding entry into phase I clinical  
523 trials. *Mol Cancer.* 2016;15: 73. doi: 10.1186/s12943-016-0553-z.
- 524 18. Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect  
525 of the run-in on the power of the Physicians' Health Study. *Stat Med.* 1991;10:  
526 1585–93 doi: 10.1002/sim.4780101010.
- 527 19. Rosenberger W. Randomized play-the-winner clinical trials: review and  
528 recommendations. *Control Clin Trials.* 1999;20: 328–42 doi: 10.1016/s0197-  
529 2456(99)00013-6.
- 530 20. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al.  
531 Phase II placebo-controlled randomized discontinuation trial of sorafenib in  
532 patients with metastatic renal cell carcinoma. *J Clin Oncol.* 2006; 24: 2505–  
533 12. doi: 10.1200/JCO.2005.03.6723.
- 534 21. Park JW, Liu MC, Yee D, Yau C, van't Veer LJ, Symmans WF, et al.  
535 Adaptive Randomization of Neratinib in Early Breast Cancer. 2016;375: 11–  
536 22. doi: 10.1056/NEJMoa1513750.
- 537 22. Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, et al.  
538 Overview, hurdles, and future work in adaptive designs: perspectives from a  
539 National Institutes of Health-funded workshop. *Clin Trials.* 2012;9: 671–80  
540 doi: 10.1177/1740774512461859.

- 541 23. Boissel JP, Kahoul R, Marin D, Boissel FH. Effect model law: an approach for  
542 the implementation of personalized medicine. *J. Pers Med.* 2013;3: 177–90.  
543 doi: 10.3390/jpm3030177.
- 544 24. Scannell JW, Bosley J. When Quality Beats Quantity: Decision Theory, Drug  
545 Discovery, and the Reproducibility Crisis. *PLoS One.* 2016;11: e0147215. doi:  
546 10.1371/journal.pone.0147215.
- 547 25. Model Informed Drug Development Pilot Program. Available from:  
548 <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm600311.htm>.  
549
- 550 26. Madabushi R, Benjamin JM, Grewal R, Pacanowski MA, Strauss DG, Wang  
551 Y, Zhu H, Zineh I. The US Food and Drug Administration's Model-Informed  
552 Drug Development Paired Meeting Pilot Program: Early Experience and  
553 Impact. *Clin Pharmacol Ther.* 2019;106: 74–8. doi: 10.1002/cpt.1457.
- 554 27. Musuamba FT, Bursi R, Manolis E, Karlsson K, Kulesza A, Courcelles E,  
555 Boissel JP, Lesage R, Crozatier C, Voisin EM, Rousseau CF, Marchal T,  
556 Alessandrello R, Geris L. Verifying and Validating Quantitative Systems  
557 Pharmacology and In Silico Models in Drug Development: Current Needs,  
558 Gaps, and Challenges. *CPT Pharmacometrics Syst Pharmacol.* 2020;9: 195–  
559 97. doi: 10.1002/psp4.12504.
- 560 28. Viceconti M, Henney A, Morley-Fletcher E. In silico Clinical trials: how  
561 computer simulation will transform the biomedical industry. *Int J Clin Trials.*  
562 2016;3: 37–46. doi:10.13140/RG.2.1.2756.6164.

Figure 1 panel A




Figure 1 panel B




Figure 1 panel C





Figure 1 panel D



## Figure 1 Relations between the proportion of responders in the trial sample and major features of the trial

Panel A, shows the linear decrease of the ethical losses expressed in percentage of unnecessary patients with the increase of the percentage of responders. Panel B, keeping the number of responders in the T group constant at  $n=121$ , the sample size drops abruptly from more than 7,000 to less than 1,000 when the responder percentage increases up to about 20% to then flatten until the “perfect” trial status is reached, meaning that only responders are enrolled. Panel C, the relative risk decreases rapidly until the responder percentage reaches about 40%, from less than 0.8 to about 0. Panel D, the chi-square value of the comparison test of mortality rates between placebo and treatment groups increases linearly as the percentage of responders increases. The probability of ascertaining significance increases as well.